FAM3C: an emerging biomarker and potential therapeutic target for cancer

FAM3C is a member of the FAM3 family. Recently, overexpression of FAM3C has been reported in numerous types of cancer, including breast and colon cancer. Increasing evidence suggests that elevated FAM3C and its altered subcellular localization are closely associated with tumor formation, invasion, metastasis and poor survival. Moreover, FAM3C has been found to be the regulator of various proteins that associate with cancer, including Ras, STAT3, TGF-beta and LIFR. This review summarizes the current knowledge regarding FAM3C, including its structure, expression patterns, regulation, physiological roles and regulatory functions in various malignancies. These findings highlight the importance of FAM3C in cancer development and provide evidence that FAM3C is a novel biomarker and potential therapeutic target for various cancers.

Automated summary

FAM3C, a member of the FAM3 family, has been reported to be overexpressed in various types of cancer and associated with tumor formation, invasion, metastasis, and poor survival. It is also known to regulate proteins like Ras, STAT3, TGF-beta, and LIFR, which are linked to cancer. This suggests that FAM3C could be a novel biomarker and potential therapeutic target for cancer treatment.